The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc., through its subsidiary Wellgistics, LLC, entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement with Marco Capital, Inc. on May 1, 2026. Wellgistics acknowledged approximately $1.77 million in outstanding obligations under a prior Loan and Security Agreement.
Under the Forbearance Agreement, Marco Capital agreed to temporarily forbear from exercising certain rights and remedies through June 15, 2026. Wellgistics must make bi-weekly payments of $50,000 starting May 5, 2026, and a portion of net proceeds from future financings during the forbearance period may need to be applied to repayment. The obligations will accrue interest at a rate equal to Term SOFR plus 11.5% per annum beginning May 5, 2026.
Wellgistics Health, Inc. filed an amended current report to correct the cover-page report date to February 9, 2026 and to restate its description of a key contract. The company explains that the material definitive agreement for disclosure purposes is an Amended Settlement Agreement entered on February 9, 2026 with Silverback Capital Corporation, which modifies an earlier settlement agreement referenced in the original report. All other disclosures from the original report remain unchanged.
Wellgistics Health, Inc. is asking stockholders at a virtual special meeting on May 21, 2026 to approve three charter and plan changes. The company seeks to change its name to Vantix Health Inc., add authorization for 10,000,000 shares of blank check preferred stock, and significantly expand its 2023 Equity Incentive Plan.
The equity plan would rise from 43,506,064 to 100,000,000 shares reserved, an increase of 56,493,936 shares, described as about 45% of common shares outstanding as of April 22, 2026. The plan’s automatic annual increase limit would also move from 3% to up to 10% of shares outstanding, at the administrator’s discretion. The board unanimously recommends voting “FOR” all three proposals.
Wellgistics Health, Inc. filed Amendment No. 1 to its annual report to update governance and ownership information. The amendment restates the sections on directors, executive officers and beneficial ownership and adds exhibits, including the company’s compensation recovery (clawback) policy.
The filing details a refreshed leadership team, including President Prashant Patel, Interim Chief Financial Officer Eric Sherb, and Chairman Suren Ajjarapu, along with three independent directors. It also describes the audit and nominating/compensation committees and confirms that Gary Herman is the audit committee financial expert.
The amendment provides a detailed beneficial ownership table as of March 2, 2026, showing significant holdings by insiders and one additional holder over 5%. It also summarizes the company’s code of ethics and insider trading policy, including blackout periods and a prohibition on short sales by employees, officers and directors.
Wellgistics Health, Inc. is asking stockholders to approve three amendments at a virtual Special Meeting on May 21, 2026: a corporate name change to Vantix Health Inc., authorization of 10,000,000 shares of blank‑check preferred stock, and an amendment to its 2023 Equity Incentive Plan to add 56,493,936 shares and change the annual automatic increase to up to 10% of outstanding shares beginning January 1, 2027.
The record date for voting is April 22, 2026, when 126,653,372 shares were outstanding. The Board recommends voting FOR all proposals; each approval requires the affirmative vote of a majority of outstanding common stock.
Wellgistics Health, Inc. reported that Chief Executive Officer Prashant Patel received significant equity compensation. On March 31, 2026, he was granted 5,000,000 shares of common stock at a stated value of $0.20 per share, increasing his direct holdings to 9,118,247 shares.
On the same date, he also received 5,000,000 warrants to purchase common stock with a $0.01 exercise price, expiring on March 31, 2031. The filing notes both the shares and warrants were issued as compensation for his service in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. director Surendra K. Ajjarapu received a large equity compensation package. On March 31, 2026, he was granted 5,000,000 shares of common stock at a stated value of $0.20 per share, bringing his direct holdings to 7,882,247 shares.
He was also granted 5,000,000 warrants to purchase common stock at an exercise price of $0.01 per share, expiring on March 31, 2031. The footnotes state both the shares and warrants were issued as compensation for his service in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Wellgistics Health, Inc. filed an amended report describing a new joint venture with Kare Pharmtech affiliates and a Nasdaq listing deficiency notice. The company agreed to form Healthstar Technologies, LLC, holding a 51% membership interest while Kare Rx Hub holds 49%.
In exchange for Kare Rx Hub transferring certain intellectual property and related assets to Healthstar, Wellgistics will pay Kare Pharmtech $2,000,000 in common stock, including 1,500,000 shares at closing and potential additional shares by April 1, 2027, based on a two-day volume-weighted average price. These unregistered shares will be restricted and subject to a 12‑month lock-up. Closing is conditioned on satisfactory due diligence, with either side able to terminate if dissatisfied.
Separately, Nasdaq notified Wellgistics that it is not in compliance with Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. The company reported stockholders’ equity of $(12,447,801) and also does not meet alternative continued listing standards. Wellgistics has until May 28, 2026 to submit a compliance plan and may receive up to 180 days from April 13, 2026 to regain compliance if Nasdaq accepts that plan.
Wellgistics Health, Inc. entered into a Collaboration Agreement to form a new limited liability company, Healthstar, with Kare Rx Hub, LLC. Wellgistics will hold a 51% membership interest and Kare Hub will hold 49%. Kare Hub will transfer specified intellectual property and related assets into Healthstar.
As consideration, Wellgistics agreed to pay Kare Pharmtech an aggregate purchase price of $2,000,000 in unregistered common stock. The agreement provides for 1,500,000 shares at closing and, at Wellgistics’ option, additional shares by April 1, 2027, based on a two-day volume-weighted average price. The Purchase Shares will be restricted, with Kare Pharmtech subject to a 12‑month lock-up from each payment date.
A related press release explains that the joint venture combines Wellgistics’ EinsteinRx™ and HubRx AI™ platforms with KareRx’s digital hub, creating an integrated ecosystem that can potentially reach more than 200,000 patient lives and support direct‑to‑patient and decentralized care models.